| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Françoise Van Bambeke | Q37828419 |
| P2093 | author name string | Françoise Van Bambeke | |
| P2860 | cites work | Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective | Q37858138 |
| Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. | Q37867464 | ||
| Clinical relevance of the ESKAPE pathogens | Q38086338 | ||
| Antibiotics in the clinical pipeline in 2013. | Q38133967 | ||
| Treatment of infections due to resistant Staphylococcus aureus | Q38148512 | ||
| Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones | Q38233471 | ||
| Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. | Q39469655 | ||
| Susceptibility of Yersinia pestis to novel and conventional antimicrobial agents | Q41466212 | ||
| A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections | Q41634906 | ||
| The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae | Q43420849 | ||
| Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus | Q44405036 | ||
| Analysis on distribution and genomic diversity of high-level antiseptic resistance genes qacA and qacB in human clinical isolates of Staphylococcus aureus | Q44487335 | ||
| ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model | Q44931262 | ||
| Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model | Q45003106 | ||
| Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model | Q46452420 | ||
| Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase | Q46862305 | ||
| Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. | Q54297668 | ||
| A new strategy to fight antimicrobial resistance: the revival of old antibiotics | Q21131083 | ||
| The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia | Q27001437 | ||
| Staphylococcus aureus biofilms: properties, regulation, and roles in human disease | Q27006715 | ||
| Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex | Q28343858 | ||
| Overexpression of patA and patB , Which Encode ABC Transporters, Is Associated with Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae | Q33715260 | ||
| Colistin in the 21st century | Q33847509 | ||
| Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. | Q33976079 | ||
| Mechanism of plasmid-mediated quinolone resistance | Q34025874 | ||
| Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus | Q34059927 | ||
| Application of fluoroquinolone pharmacodynamics | Q34076026 | ||
| Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas | Q34230978 | ||
| Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus | Q34528916 | ||
| Comparison of the antibiotic activities of Daptomycin, Vancomycin, and the investigational Fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates. | Q34596619 | ||
| Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence | Q34722890 | ||
| Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 | Q35013962 | ||
| Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 | Q35014040 | ||
| Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy | Q35107933 | ||
| In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms | Q35125137 | ||
| In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis | Q35685125 | ||
| In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone | Q36048301 | ||
| Quinolones in 2005: an update. | Q36067593 | ||
| Mutant selection window hypothesis updated. | Q36728061 | ||
| New antibiotic agents in the pipeline and how they can help overcome microbial resistance | Q36845895 | ||
| A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. | Q37026608 | ||
| Antimicrobial resistance in Asia: current epidemiology and clinical implications | Q37192102 | ||
| Staphylococcus aureus: new evidence for intracellular persistence | Q37390102 | ||
| Effect of mild acid on gene expression in Staphylococcus aureus | Q37663651 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| pharmacodynamics | Q725307 | ||
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 1111-23 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Future Microbiology | Q15759961 |
| P1476 | title | Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy | |
| P478 | volume | 10 |
| Q92982984 | A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP) |
| Q54259788 | A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study. |
| Q64066320 | Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections |
| Q64066297 | Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections |
| Q30249262 | Antibiotics in the clinical pipeline at the end of 2015. |
| Q90131070 | Antimicrobial resistance in methicillin-resistant Staphylococcus aureus to newer antimicrobial agents |
| Q39445047 | Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment |
| Q41989976 | Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. |
| Q64066316 | Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections |
| Q64066325 | Current Treatment Options for Acute Skin and Skin-structure Infections |
| Q88923191 | Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone |
| Q48100715 | Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function |
| Q94340220 | Delafloxacin for the Treatment of Acute Bacterial Skin and Skin Structure Infections |
| Q34554381 | Delafloxacin: design, development and potential place in therapy |
| Q50065370 | Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study |
| Q36887890 | In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance. |
| Q40342746 | In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014 |
| Q38375319 | In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections |
| Q39362169 | Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon |
| Q38940456 | Managing the oncologic patient with suspected pneumonia in the intensive care unit |
| Q88924840 | Methicillin-resistant Staphylococcus aureus |
| Q40111519 | New treatment options for lower respiratory tract infections |
| Q92703641 | Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms |
| Q64066306 | Profile of a Novel Anionic Fluoroquinolone-Delafloxacin |
| Q38958278 | Recent Advances in the Rational Design and Optimization of Antibacterial Agents |
| Q57822396 | Safety of Delafloxacin: Focus on Adverse Events of Special Interest |
| Q37396221 | The antifungal caspofungin increases fluoroquinolone activity against Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase. |
| Q90312140 | Underscoring interstrain variability and the impact of growth conditions on associated antimicrobial susceptibilities in preclinical testing of novel antimicrobial drugs |
Search more.